Format

Send to

Choose Destination
Int J Clin Exp Pathol. 2015 May 1;8(5):4332-43. eCollection 2015.

Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis.

Author information

1
Department of Critical Care Medicine, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.
2
Department of General Surgery, Shengjing Hospital of China Medical University Shenyang 110004, People's Republic of China.

Abstract

Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high mortality and multiple organ injuries including renal injury. Rosiglitazone (Ros), an agonist of peroxisome proliferator activated receptor-γ (PPAR-γ), was reported to show a protective role against pancreatitis. However, whether Ros has an effect on renal injury caused by HP is not yet clear. In the present study, the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining and immunohistochemistry. Results of this study showed that Ros could inhibit the activation of NF-κB and MAPK P38 signaling pathways, relieve inflammatory response and inhibit cell apoptosis, thus attenuating renal injury caused by HP. This study suggested that Ros might be a promising drug for the treatment of renal injury caused by HP and also laid theoretical foundation for the development of renal injury treatment.

KEYWORDS:

Rosiglitazone; apoptosis; hyperlipidemic pancreatitis; inflammation; renal injury

PMID:
26191125
PMCID:
PMC4502997
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center